Passa al contenuto
Merck

Central role of mTORC1 downstream of YAP/TAZ in hepatoblastoma development.

Oncotarget (2017-11-02)
Pin Liu, Diego F Calvisi, Andras Kiss, Antonio Cigliano, Zsuzsa Schaff, Li Che, Silvia Ribback, Frank Dombrowski, Dongchi Zhao, Xin Chen
ABSTRACT

Hepatoblastoma (HB) is the most common type of liver malignancy in children. Recent studies suggest that activation of Yes-associated protein (YAP) is a major molecular event in HB development, as activated YAP synergizes with mutant β-catenin to promote HB formation in mice (YAP/β-catenin). However, how YAP regulates HB development remains poorly defined. Similarly, de-regulation of mammalian target of rapamycin complex 1 (mTORC1) signaling has been implicated in multiple tumor types, but its functional role in HB development is scarcely understood. In the present study, we found that mTORC1 is activated in human HB cells and YAP/β-catenin-induced mouse HB tumor tissues. mTOR inhibitor MLN0128 significantly inhibits human HB cell growth

MATERIALI
N° Catalogo
Marchio
Descrizione del prodotto

Sigma-Aldrich
Anti-β-actina monoclonale, clone AC-15, ascites fluid
Sigma-Aldrich
Anticorpo clone 6C5 anti-gliceraldeide-3-fosfato deidrogenasi, clone 6C5, Chemicon®, from mouse
Sigma-Aldrich
3-(Biphenyl-4-yl)-5-(4-tert-butylphenyl)-4-phenyl-4H-1,2,4-triazole, 97%
Sigma-Aldrich
Anti-SLC38A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution